Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tatsuya Ogimoto"'
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Chronic obstructive pulmonary disease (COPD) may coexist with lung cancer, but the impact on prognosis is uncertain. Moreover, it is unclear whether pharmacological treatment for COPD improves the patient’s prognosis. We retrospectively in
Externí odkaz:
https://doaj.org/article/f3c791af74a046499c35180097eeba07
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/54a067459b054ee180ce6a077620ee5a
Autor:
Takafumi Yamaya, Hwang Moon Hee, Takayuki Aoyagi, Tatsuya Ogimoto, Naoki Yamada, Ryoichi Ishikawa, Erika Nakai, Kenta Nishi, Chie Yoshimura, Yasuo Nishizaka
Publikováno v:
Respiratory Medicine Case Reports, Vol 28, Iss , Pp - (2019)
Immune checkpoint inhibitors (ICIs) have been used to treat lung cancer. Several types of ICI-related interstitial lung diseases have been reported, including organizing pneumonia, non-specific interstitial pneumonia, and diffuse alveolar damage. How
Externí odkaz:
https://doaj.org/article/fc8951c2bb3b4e79b1537287ac5588fe
Autor:
TATSUYA OGIMOTO1 ozahiro@kuhp.kyoto-u.ac.jp, HIROAKI OZASA1, HIRONORI YOSHIDA1, TAKASHI NOMIZO1, TOMOKO FUNAZO1, HIROSHI YOSHIDA1, KENTARO HASHIMOTO1, KAZUTAKA HOSOYA1, MASATOSHI YAMAZOE1, HITOMI AJIMIZU1, TAKAHIRO TSUJI1,2, YUICHI SAKAMORI1, KIYOMITSU KUNINAGA1, SATOSHI MORITA3, TOYOHIRO HIRAI1
Publikováno v:
Oncology Letters. Aug2023, Vol. 26 Issue 2, p1-7. 7p.
Autor:
Masatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Tatsuya Ogimoto, Hitomi Ajimizu, Hironori Yoshida, Ryo Itotani, Yuichi Sakamori, Kiyomitsu Kuninaga, Wataru Aoki, Toyohiro Hirai
Publikováno v:
Cancer scienceREFERENCES.
Tyrosine kinase inhibitors (TKIs) that target the ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene have shown dramatic therapeutic effects in patients with ROS1-rearranged non-small-cell lung cancer (NSCLC). Nevertheless, advanced ROS1-rear
Autor:
Kentaro Hashimoto, Hiroaki Ozasa, Akihiko Yoshizawa, Hiroshi Yoshida, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Funazo, Hironori Yoshida, Yuichi Sakamori, Toyohiro Hirai
Publikováno v:
Oncology letters. 24(5)
Immune checkpoint therapy (ICT) with nivolumab has been widely used to treat malignant pleural mesothelioma (MPM) since clinical trials confirmed its efficacy. However, only a few clinical trials have been conducted for the treatment of sarcomatoid M
Autor:
Tomoko Funazo, Hironori Yoshida, Masatoshi Yamazoe, Toyohiro Hirai, Tatsuya Ogimoto, Kiyomitsu Kuninaga, Takashi Nomizo, Kazutaka Hosoya, Hitomi Ajimizu, Yuto Yasuda, Hiroaki Ozasa, Yuichi Sakamori, Young Hak Kim, Ryo Itotani, Takahiro Tsuji
Publikováno v:
European Journal of Cancer. 144:317-325
Background We previously reported that PD-L1 polymorphisms are associated with the efficacy and immune-related adverse events of PD-1 blockade with nivolumab. However, the association between PD-L1 polymorphisms and survival outcomes under PD-1/PD-L1
Publikováno v:
Investigational new drugs. 40(2)
Nivolumab, a programmed death 1 blockade drug, is used in various types of cancers and can cause a unique immune-related adverse event (irAE). Relapsing polychondritis (RP) is a rare autoimmune disease that mainly involves inflammation of the auricle
Autor:
Tomoko Y. Funazo, Hiroaki Ozasa, Kentaro Hashimoto, Hiroshi Yoshida, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Yuichi Sakamori, Toyohiro Hirai
Publikováno v:
Cancer Research. 82:1601-1601
Overcoming the treatment resistance of cancer is a problem to be solved in improving the prognosis of cancer patients. Recently, genome analysis has revealed that multiple clusters exist in one tumor, and it has been reported that intratumor heteroge
Autor:
Tatsuya Ogimoto, Hiroaki Ozasa, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Yuichi Sakamori, Toyohiro Hirai
Publikováno v:
Cancer Research. 82:5335-5335
Background: EGFR mutation-positive lung cancer has high response rates to EGFR-tyrosine kinase inhibitors (TKIs), but eventually acquires resistance to EGFR-TKIs. Acquired resistance mechanisms are diverse because of tumor heterogeneity, which makes